Jeannie Baumann

Iowa’s ongoing abortion battle will hinge on whether state justices decide the US Supreme Court’s Dobbs ruling last year changes the legal test on whether a ban on the procedure after six-weeks of pregnancy is constitutional in the state.

Major health-care business deals will undergo greater oversight from state regulators as part of a larger effort to rein in soaring health spending.

A California oversight agency proposed a $25 million annual revenue threshold for most health transactions that would trigger new notice requirements as a way to address rising medical costs.

WASHINGTON — The National Institutes of Health selected Jeanne Marrazzo to lead the nation’s top infectious disease research agency, securing a successor to Anthony Fauci, who held the role for

A US plan to restrict investment in China is likely to apply only to Chinese companies that get at least half of their revenue from cutting-edge sectors.

Monica Vetter typically would treat the cervical cancer on “Patient M” with a low dose of chemotherapy and a high dose of radiation. But Patient M was 21 weeks pregnant and living in Kentucky, which took the recommended treatment off the table.

The drugmakers suing the US government in multiple courts to block drug price negotiations are doing so for good reason—they’re the ones that stand to lose the most in Medicare’s first-ever plan to control the cost of medicines it spends the most on.

Major drugmakers have assembled an army of top attorneys from the nation’s most prestigious firms to take down Medicare’s drug price negotiation program, hoping to take advantage of experience gained in health litigation, arguments before the Supreme Court, and policymaking inside the federal government.

Federal courts grappling with challenges to state transgender care bans are diverging on whether such bans run afoul of constitutional rights.

(Bloomberg) -- US Food and Drug Administration Deputy Commissioner Janet Woodcock will retire next year after nearly four decades at the regulator